Cargando…
Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients
Circulating tumor cells (CTCs) are promising tools for risk prediction and the monitoring of response to therapy in cancer patients. Within the EU/IMI CANCER-ID consortium, we validated CTC enrichment systems for future inclusion into clinical trials. Due to the known heterogeneity of markers expres...
Autores principales: | Koch, Claudia, Joosse, Simon A., Schneegans, Svenja, Wilken, Okka J. W., Janning, Melanie, Loreth, Desiree, Müller, Volkmar, Prieske, Katharina, Banys-Paluchowski, Malgorzata, Horst, Ludwig J., Loges, Sonja, Peine, Sven, Wikman, Harriet, Gorges, Tobias M., Pantel, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072175/ https://www.ncbi.nlm.nih.gov/pubmed/32069934 http://dx.doi.org/10.3390/cancers12020442 |
Ejemplares similares
-
CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis
por: Loreth, Desiree, et al.
Publicado: (2021) -
Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer
por: Hanssen, Annkathrin, et al.
Publicado: (2015) -
BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
por: Elazezy, Maha, et al.
Publicado: (2021) -
Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay
por: Belloum, Yassine, et al.
Publicado: (2020) -
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)